Bayer HealthCare submits VEGF Trap-Eye MAA in Europe
VEGF Trap-Eye, a human fusion protein consisting of portions of VEGF receptors 1 and 2, binds all forms of VEGF-A along with the related Placental Growth Factor (PlGF).
miRecule has signed a research collaboration with EM subsidiary Rio Biofarma Brasil (RBBL) to co-develop peptide-mediated delivery technologies aimed at improving targeted ribonucleic acid (RNA) therapeutics delivery to tissues beyond the liver and muscles in a range of disease areas.
PROLOR Biotech uses patented CTP technology and its Reversible PEGylation technology to develop longer-acting, proprietary versions of already approved therapeutic proteins to increase half-life of the drug candidate.